Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515784 | 0.87 | CNR2 (0.53) | CNR2CNR1PLA2G2AKDM4EHSD17B10 | |
| SCHEMBL25515494 | 0.80 | CNR2 (0.48) | CNR2PLA2G2A | |
| SCHEMBL25515534 | 0.79 | CNR2 (0.49) | CNR2CNR1KDM4EHRH2HRH1 | |
| SCHEMBL25515782 | 0.79 | CNR2 (0.54) | CNR2PLA2G2A | |
| SCHEMBL25515593 | 0.79 | CNR2 (0.47) | CNR2CNR1HRH2HRH1 | |
| SCHEMBL25515727 | 0.78 | CNR2 (0.48) | CNR2CNR1PSEN1PSEN2APH1B | |
| SCHEMBL25515570 | 0.77 | TUBB4A (0.43) | CNR2KDM4EALDH1A1 | |
| SCHEMBL3379507 | 0.77 | HDAC8 (0.62) | ALDH1A1 | |
| SCHEMBL25515517 | 0.76 | CNR2 (0.47) | CNR2CNR1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL25515644 | 0.76 | CNR2 (0.46) | CNR2PLA2G2AHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021175855-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | CNR2 663/4885CNR1 878/4885PSEN1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.